NRSN Neurosense Therapeutics Ltd
Company Analysis
Latest News
NeuroSense Fast-Tracks PrimeC Development, Cutting Costs for ALS Drug Approval
NeuroSense Therapeutics has redesigned its development plan for PrimeC to treat amyotrophic lateral sclerosis (ALS). The new strategy replaces a single large...
🟢 Neurosense Therapeutics is trading 13.23% up today in pre-market; catalyst remains unclear
Neurosense Therapeutics is trading 13.23% higher at $0.48 after rising from the August 28 close of $0.42, with no clear catalyst identified. - No fresh...
🟢 Neurosense Therapeutics is trading 7% up in pre-market with no clear catalyst identified
Neurosense Therapeutics is trading 7.04% up at $0.45, with no fresh company-specific announcement for August 31, 2026 identified. - It reached $0.42 at the...
🟢 Neurosense Therapeutics is trading 7.12% up today
Neurosense Therapeutics is trading 7.12% up at $0.45, extending gains from the August 27 close of $0.44 and August 26 close of $0.41. - No fresh...
🟢 Neurosense Therapeutics is trading 5.16% up today amid stronger biotechnology sentiment
Neurosense Therapeutics is trading 5.16% up at $0.43, extending the August 26, 2026 close of $0.41 after a 6.98% gain, amid stronger biotechnology sentiment...
🟢 Neurosense Therapeutics is trading 13.1% up today amid biotech-sector strength
Neurosense Therapeutics is trading 13.1% up at $0.43, with the move appearing primarily supported by biotechnology-sector strength. - XBI is up 2.06% during...
🟢 Neurosense Therapeutics is trading 6.96% up today as XBI gains 2.06%
Neurosense Therapeutics is trading 6.96% up at $0.41, supported primarily by a broader biotech-sector rally, with XBI up 2.06% during the regular session. -...
🟢 Neurosense Therapeutics is trading 6.72% up in pre-market — no confirmed company-specific catalyst
Neurosense Therapeutics is trading 6.72% up at $0.41 after an overnight move with no confirmed company-specific catalyst. - A special shareholder meeting is...
🟢 Neurosense Therapeutics is trading 5.57% up in after-hours trading amid broader biotech strength
Neurosense Therapeutics is trading 5.57% up now at $0.40 amid broader biotech-sector momentum, with XBI up 2.06% and no confirmed company-specific announcement...
🟢 Neurosense Therapeutics is trading 6.37% up today as XBI gains 2.06%
Neurosense Therapeutics is trading 6.37% up now at $0.40, with the advance best explained by broader biotech-sector strength as XBI rises 2.06%. - No...
🟢 Neurosense Therapeutics is trading 5.16% up in pre-market with no confirmed fresh catalyst
Neurosense Therapeutics is trading 5.16% up in pre-market at $0.40, after closing at $0.38 on August 21, 2026, with no confirmed fresh catalyst identified. -...
🟢 Neurosense Therapeutics is trading 11.30% up today after August 20 selloff
Neurosense Therapeutics is trading 11.30% up at $0.39 after rebounding from its August 20 close of $0.35. - Shares fell 11.96% on August 20. - No new...
🔴 Neurosense Therapeutics is trading 12.04% down today amid delays securing Phase 3 financing
Neurosense Therapeutics is trading 12.04% down now at $0.35 after investors continued reacting to disclosed delays in securing financing for the Phase 3...
🔴 Neurosense Therapeutics is trading 7.06% down today amid concerns over Phase 3 funding delays
Neurosense Therapeutics is trading at $0.37 (-7.06%) amid broader biotech and market weakness; no confirmed August 20, 2026 company-specific announcement...
🔴 Neurosense Therapeutics is trading 10.97% down today; no specific catalyst confirmed
Neurosense Therapeutics is trading at $0.34, down -10.97%, with no specific catalyst confirmed. • No credible company-specific announcement dated August 19,...
🟢 Neurosense Therapeutics rises 7.3% — Biotech Sector Surges on Positive mRNA Cancer Vaccine Trial Results
With Biotech (XBI) up 3.7%, this looks like a sector-led move rather than a company-specific surprise. The biotech sector, proxied by the XBI ETF, is trading...
🟢 Neurosense Therapeutics is trading 6.81% up in pre-market following continued after-hours strength despite no confirmed company-specific catalyst
Neurosense Therapeutics is trading now 6.81% up at $0.41 after closing at $0.38 on August 18, 2026, following continued after-hours strength without a...
🟢 Neurosense Therapeutics is trading 12% up in after-hours trading with no confirmed catalyst
Neurosense Therapeutics is trading at $0.43, up 12.02% in after-hours trading, with no confirmed company-specific catalyst. - It closed at $0.38 on August 18,...
🟢 Neurosense Therapeutics is trading 5% up in after-hours trading without a confirmed company catalyst
Neurosense Therapeutics is trading 5% up in after-hours trading at $0.40 after the August 18, 2026 close of $0.38, reflecting limited positioning rather than a...
🔴 Neurosense Therapeutics is trading 11% down today amid broad risk-off selling
Neurosense Therapeutics is trading 11% down at $0.39 amid broad risk-off selling on August 18, 2026. - Nasdaq Composite and S&P 500 fell as technology shares...